Cargando…

Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies

Immune checkpoint inhibitors (ICIs) confer remarkable therapeutic benefits to patients with various cancers. However, many patients are non-responders or develop resistance following an initial response to ICIs. There are no reliable biomarkers to predict the therapeutic effect of ICIs. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohkuma, Ryotaro, Ieguchi, Katsuaki, Watanabe, Makoto, Takayanagi, Daisuke, Goshima, Tsubasa, Onoue, Rie, Hamada, Kazuyuki, Kubota, Yutaro, Horiike, Atsushi, Ishiguro, Tomoyuki, Hirasawa, Yuya, Ariizumi, Hirotsugu, Tsurutani, Junji, Yoshimura, Kiyoshi, Tsuji, Mayumi, Kiuchi, Yuji, Kobayashi, Shinichi, Tsunoda, Takuya, Wada, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698555/ https://www.ncbi.nlm.nih.gov/pubmed/34944745 http://dx.doi.org/10.3390/biomedicines9121929

Ejemplares similares

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary
por: Suzuki, Risako, et al.
Publicado: (2023)

High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer
por: Ohkuma, Ryotaro, et al.
Publicado: (2020)

High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer
por: Ohkuma, Ryotaro, et al.
Publicado: (2020)

A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022)

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
por: Hirasawa, Yuya, et al.
Publicado: (2021)

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)

High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer
por: Ohkuma, Ryotaro, et al.
Publicado: (2020)

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan
por: Satoh, Etsuko, et al.
Publicado: (2018)

The Sympathetic Nervous System Contributes to the Establishment of Pre-Metastatic Pulmonary Microenvironments
por: Ieguchi, Katsuaki, et al.
Publicado: (2022)

Roles of EphA1/A2 and ephrin‐A1 in cancer
por: Ieguchi, Katsuaki, et al.
Publicado: (2019)

Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
por: Hamada, Kazuyuki, et al.
Publicado: (2022)

Human Serum Amyloid A3 (SAA3) Protein, Expressed as a Fusion Protein with SAA2, Binds the Oxidized Low Density Lipoprotein Receptor
por: Tomita, Takeshi, et al.
Publicado: (2015)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

First-principles investigation on the segregation of Pd at LaFe(1-x)Pd(x)O(3-y) surfaces
por: Tian, Zhi-xue, et al.
Publicado: (2013)

PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Ravindran Menon, Dinoop, et al.
Publicado: (2021)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice
por: Tsuruta, Akito, et al.
Publicado: (2022)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2020)

Pd Nanoparticles and Thin Films for Room Temperature Hydrogen Sensor
por: Joshi, Rakesh K, et al.
Publicado: (2009)

Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix
por: Takayanagi, Daisuke, et al.
Publicado: (2021)

Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD
por: de la Fuente-Fernández, Raúl
Publicado: (2013)

The Evolution of Pd(0)/Pd(II)-Catalyzed Aromatic Fluorination
por: Sather, Aaron C., et al.
Publicado: (2016)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Photoluminescence of PdS(2) and PdSe(2) quantum dots
por: Wang, Xinyu, et al.
Publicado: (2019)

PD-1/PD-L Axis in Neuroinflammation: New Insights
por: Manenti, Susanna, et al.
Publicado: (2022)

Interlayer Coordination of Pd–Pd Units in Exfoliated Black Phosphorus
por: Vanni, Matteo, et al.
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

(CAAC)Pd(py) Catalysts Disproportionate to Pd(CAAC)(2)
por: Marigo, Nicola, et al.
Publicado: (2023)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sb99lao8tol5a2fmpulvlq4dac